Screener
Tyra Biosciences, Inc. TYRA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $84,955 | $77,387 |
| Marketable securities | 298,511 | 178,616 |
| Prepaid expenses and other current assets | 11,147 | 9,447 |
| Total current assets | 394,613 | 265,450 |
| Restricted cash | 884 | 1,000 |
| Property and equipment, net | 1,215 | 1,314 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s cash & equivalents?
- Tyra Biosciences, Inc. (TYRA) reported cash & equivalents of $84.96M in Q1 2026.
- How has Tyra Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Tyra Biosciences, Inc.'s cash & equivalents decreased by 15.7% year-over-year, from $100.72M to $84.96M.
- What is the long-term trend for Tyra Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s cash & equivalents has grown at a 38.4% compound annual growth rate (CAGR), from $15.22M to $77.39M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Tyra Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude